Treatment of community-acquired lower respiratory tract infections with oral cefuroxime axetil.

The subjects were adult hospitalized patients, 12 with pneumonia and eight with acute bronchitis. The patients with pneumonia received 500 mg of cefuroxime orally twice daily and the patients with bronchitis received 250 mg twice daily. Treatment lasted for ten days in responsive patients. The pathogens identified in the patients' sputum were Streptococcus pneumoniae, Klebsiella pneumoniae, Haemophilus influenzae, Enterobacter aerogenes, Staphylococcus aureus, or Branhamella catarrhalis. Clinical and bacteriologic cures were achieved in 11 of the 12 patients with pneumonia and in seven of the eight patients with bronchitis. It is concluded that cefuroxime axetil is safe and effective in the treatment of community-acquired pneumonia or acute bronchitis.
AuthorsB M Limson, M D Garvez
JournalClinical therapeutics (Clin Ther) 1990 Sep-Oct Vol. 12 Issue 5 Pg. 436-9 ISSN: 0149-2918 [Print] UNITED STATES
PMID2268866 (Publication Type: Journal Article)
Chemical References
  • cefuroxime axetil
  • Cefuroxime
  • Administration, Oral
  • Bacterial Infections (drug therapy)
  • Bronchitis (drug therapy)
  • Cefuroxime (administration & dosage, analogs & derivatives, therapeutic use)
  • Female
  • Humans
  • Male
  • Pneumonia, Pneumococcal (drug therapy)
  • Sputum (microbiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: